{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:27:11Z","timestamp":1793039231205,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiotensin II type 1 receptors (AT1Rs) are expressed on podocytes, endothelial and other cells, and play an essential role in the maintenance of podocyte function and vascular homeostasis. The presence of AT1R antibodies (AT1R-Abs) leads to activation of these receptors resulting in podocyte injury and endothelial cell dysfunction. We assessed the correlation between AT1R-Abs and the risk of post-transplant FSGS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective study, which included all kidney transplant recipients with positive AT1R-Abs (\u2265 9\u2009units\/ml), who were transplanted and followed at our center between 2006 and 2016. We assessed the development of biopsy proven FSGS and proteinuria by urine protein to creatinine ratio of \u22651\u2009g\/g and reviewed short and long term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 100 patients with positive AT1R-Abs at the time of kidney transplant biopsy or proteinuria. 49% recipients (FSGS group) had biopsy-proven FSGS and\/or proteinuria and 51% did not (non-FSGS group). Pre-transplant hypertension was present in 89% of the FSGS group compared to 72% in the non-FSGS group,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027. Of the FSGS group, 43% were on angiotensin converting enzyme inhibitors or angiotensin receptor blockers prior to transplantation, compared to 25.5% in the non-FSGS group,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06. Primary idiopathic FSGS was the cause of ESRD in 20% of the FSGS group, compared to 6% in the non-FSGS group,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03. The allograft loss was significantly higher in the FSGS group 63% compared to 39% in non-FSGS. Odds ratio and 95% confidence interval were 2.66 (1.18\u20135.99),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest a potential association between AT1R-Abs and post-transplant FSGS leading to worse allograft outcome. Therefore, AT1R-Abs may be considered biomarkers for post-transplant FSGS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-01910-w","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T05:25:31Z","timestamp":1593667531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria"],"prefix":"10.1186","volume":"21","author":[{"given":"Mohammad","family":"Abuzeineh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amtul","family":"Aala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Alasfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-2455","authenticated-orcid":false,"given":"Nada","family":"Alachkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"issue":"6","key":"1910_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMoa035717","volume":"352","author":"D Dragun","year":"2005","unstructured":"Dragun D, M\u00fcller DN, Br\u00e4sen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558\u201369. https:\/\/doi.org\/10.1056\/NEJMoa035717.","journal-title":"N Engl J Med"},{"issue":"8","key":"1910_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nm.1856","volume":"14","author":"CC Zhou","year":"2008","unstructured":"Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14(8):855\u201362. https:\/\/doi.org\/10.1038\/nm.1856.","journal-title":"Nat Med"},{"issue":"10","key":"1910_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMc1207233","volume":"368","author":"N Alachkar","year":"2013","unstructured":"Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med. 2013;368(10):971\u20133. https:\/\/doi.org\/10.1056\/NEJMc1207233.","journal-title":"N Engl J Med"},{"issue":"4","key":"1910_CR4","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.ajpath.2011.06.033","volume":"179","author":"T Nijenhuis","year":"2011","unstructured":"Nijenhuis T, Sloan AJ, Hoenderop JGJ, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179(4):1719\u201332. https:\/\/doi.org\/10.1016\/j.ajpath.2011.06.033.","journal-title":"Am J Pathol"},{"issue":"6","key":"1910_CR5","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.2353\/ajpath.2007.060484","volume":"170","author":"K Suzuki","year":"2007","unstructured":"Suzuki K, Han GD, Miyauchi N, et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol. 2007;170(6):1841\u201353. https:\/\/doi.org\/10.2353\/ajpath.2007.060484.","journal-title":"Am J Pathol"},{"issue":"3","key":"1910_CR6","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1097\/TP.0000000000002008","volume":"102","author":"S Alasfar","year":"2018","unstructured":"Alasfar S, Matar D, Montgomery RA, et al. Rituximab and therapeutic plasma exchange in recurrent focal segmental Glomerulosclerosis Postkidney transplantation. Transplantation. 2018;102(3):e115\u201320. https:\/\/doi.org\/10.1097\/TP.0000000000002008.","journal-title":"Transplantation."},{"issue":"1","key":"1910_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ndt\/gfp538","volume":"25","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2010;25(1):25\u201331. https:\/\/doi.org\/10.1093\/ndt\/gfp538.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"issue":"5","key":"1910_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.ackd.2014.05.010","volume":"21","author":"J Reiser","year":"2014","unstructured":"Reiser J, Nast CC, Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014;21(5):417\u201321. https:\/\/doi.org\/10.1053\/j.ackd.2014.05.010.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"17","key":"1910_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMc1202500","volume":"366","author":"L Gallon","year":"2012","unstructured":"Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med. 2012;366(17):1648\u20139. https:\/\/doi.org\/10.1056\/NEJMc1202500.","journal-title":"N Engl J Med"},{"issue":"14","key":"1910_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/NEJM199604043341402","volume":"334","author":"VJ Savin","year":"1996","unstructured":"Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334(14):878\u201383. https:\/\/doi.org\/10.1056\/NEJM199604043341402.","journal-title":"N Engl J Med"},{"issue":"8","key":"1910_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","volume":"17","author":"C Wei","year":"2011","unstructured":"Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952\u201360. https:\/\/doi.org\/10.1038\/nm.2411.","journal-title":"Nat Med"},{"issue":"11","key":"1910_CR12","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2215\/CJN.03800609","volume":"5","author":"ET McCarthy","year":"2010","unstructured":"McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol CJASN. 2010;5(11):2115\u201321. https:\/\/doi.org\/10.2215\/CJN.03800609.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"7","key":"1910_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ctr.12562","volume":"29","author":"MA Mujtaba","year":"2015","unstructured":"Mujtaba MA, Sharfuddin AA, Book BL, et al. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence. Clin Transpl. 2015;29(7):606\u201311. https:\/\/doi.org\/10.1111\/ctr.12562.","journal-title":"Clin Transpl"},{"issue":"3","key":"1910_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/TP.0000000000001231","volume":"101","author":"MC Philogene","year":"2017","unstructured":"Philogene MC, Bagnasco S, Kraus ES, et al. Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies. Transplantation. 2017;101(3):608\u201315. https:\/\/doi.org\/10.1097\/TP.0000000000001231.","journal-title":"Transplantation."},{"issue":"4","key":"1910_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.humimm.2018.02.001","volume":"79","author":"MC Philogene","year":"2018","unstructured":"Philogene MC, Zhou S, Lonze BE, et al. Pre-transplant screening for non-HLA antibodies: who should be tested? Hum Immunol. 2018;79(4):195\u2013202. https:\/\/doi.org\/10.1016\/j.humimm.2018.02.001.","journal-title":"Hum Immunol"},{"issue":"7","key":"1910_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/TP.0b013e31829eda4f","volume":"96","author":"N Alachkar","year":"2013","unstructured":"Alachkar N, Wei C, Arend LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation. 2013;96(7):649\u201356. https:\/\/doi.org\/10.1097\/TP.0b013e31829eda4f.","journal-title":"Transplantation."},{"issue":"3","key":"1910_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1600-6143.2009.02987.x","volume":"10","author":"B Sis","year":"2010","unstructured":"Sis B, Mengel M, Haas M, et al. Banff \u201809 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2010;10(3):464\u201371. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02987.x.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg."},{"issue":"2","key":"1910_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12590","volume":"14","author":"M Haas","year":"2014","unstructured":"Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2014;14(2):272\u201383. https:\/\/doi.org\/10.1111\/ajt.12590.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg."},{"issue":"1","key":"1910_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.14107","volume":"17","author":"A Loupy","year":"2017","unstructured":"Loupy A, Haas M, Solez K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2017;17(1):28\u201341. https:\/\/doi.org\/10.1111\/ajt.14107.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg."},{"issue":"2","key":"1910_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","volume":"18","author":"M Haas","year":"2018","unstructured":"Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2018;18(2):293\u2013307. https:\/\/doi.org\/10.1111\/ajt.14625.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg."},{"issue":"1","key":"1910_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/TP.0000000000002320","volume":"103","author":"T Alhamad","year":"2019","unstructured":"Alhamad T, Manllo Dieck J, Younus U, et al. ACTH gel in resistant focal segmental Glomerulosclerosis after kidney transplantation. Transplantation. 2019;103(1):202\u20139. https:\/\/doi.org\/10.1097\/TP.0000000000002320.","journal-title":"Transplantation."},{"issue":"2","key":"1910_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1600-6143.2012.04338.x","volume":"13","author":"J Lopez-Hellin","year":"2013","unstructured":"Lopez-Hellin J, Cantarell C, Jimeno L, et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2013;13(2):493\u2013500. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04338.x.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"issue":"11","key":"1910_CR23","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1097\/01.tp.0000264554.39645.74","volume":"83","author":"J Pascual","year":"2007","unstructured":"Pascual J, Mezrich JD, Djamali A, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation. 2007;83(11):1429\u201334. https:\/\/doi.org\/10.1097\/01.tp.0000264554.39645.74.","journal-title":"Transplantation."},{"issue":"2","key":"1910_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2215\/CJN.03751106","volume":"2","author":"E Letavernier","year":"2007","unstructured":"Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol CJASN. 2007;2(2):326\u201333. https:\/\/doi.org\/10.2215\/CJN.03751106.","journal-title":"Clin J Am Soc Nephrol CJASN."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01910-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01910-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01910-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:11:35Z","timestamp":1625166695000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01910-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01910-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-19193\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"23 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a retrospective chart review study approved by the Johns Hopkins Hospital Institutional Review Board (IRB). Patient\u2019s consent was waived. All ethics in conducting retrospective chart review research were followed closely.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Nada Alachkar is a Section Editor of BMC Nephrology-Transplantation Section.No other financial and non-financial competing interests for any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}